Please Find the Enclosed herewith Audited Results for FY 31 march 2025

Net loss reportedNegative operating cash flowEBITDA margin compressionDebt to equity above the thresholdRevenue growth above 20%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹7.15

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-2.1% vs market

Healthcare Service Provider peers, median of 23sector-0.5%-1.5% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.1-2.1-0.5-1.5

Next day

-0.4-0.2-0.2-0.2-0.2

—+0.3—-0.1—

-2.0+0.9-2.8+0.0-2.0

-3.9+0.8-4.7+0.4-4.3

+0.8+2.2-1.3+1.2-0.3

+2.8+3.4-0.6+0.4+2.4

15d

+15.8-0.8+16.6+1.0+14.8

+2.9+2.9+0.0+1.2+1.7

+9.1+0.8+8.2+14.0-4.9

+18.5+0.0+18.5+10.3+8.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Boston Bio Systems Limited reported audited standalone results for FY25 with revenue from operations of Rs. 19.25 lakhs, up from nil in the previous year. Total expenses rose sharply to Rs. 73.98 lakhs (vs Rs. 14.07 lakhs), driven mostly by other expenses, leading to a net loss of Rs. 54.73 lakhs compared with a loss of Rs. 14.07 lakhs in FY24. The auditor (M/s Nahar V & Company) issued an unmodified opinion, and the board approved the results at its meeting on 30 May 2025. The balance sheet shows total assets of Rs. 1,490.37 lakhs against shareholders' funds of only Rs. 590.45 lakhs, with negative other equity of Rs. 109.77 lakhs. Cash flow from operations was deeply negative at Rs. (458.46) lakhs, which the company funded almost entirely by taking on Rs. 457.48 lakhs in fresh borrowings, pushing non-current borrowings from Rs. 11.62 lakhs to Rs. 459.29 lakhs.

Likely market impact

The company is loss-making, burning cash from operations and leaning heavily on debt to stay afloat, which is a red flag for shareholders despite the clean audit opinion. With negative net worth components, rising debt, and no clear earnings visibility, the stock remains a high-risk, speculative name.